Sun Pharma Exhales After FDA Clearance
Attachment: halol
Sun Pharma is celebrating as the U.S. Food and Drug Administration (FDA) has finally cleared its Halol drug plant in western India. Thanks to a slew of quality control problems at one of its key generic manufacturing plants, India's largest drug maker has been under supply restrictions. The problem dates back to 2014, when Sun first received an FDA Form 483 for the site, followed shortly thereafter with a formal warning letter, citing serious sterility concerns.
